Stabilized liquid anti-RSV antibody formulations
The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
1. A method of preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a subject, said method comprising administering a prophylactically or therapeutically effective amount of a liquid palivizumab formulation, said formulation comprising in an aqueous carrier: (a) at least 15 mg/ml of palivizumab, or an antigen-binding fragment thereof; and (b) histidine at a concentration of about 1 mM to about 100 mM, wherein said formulation is substantially free of surfactant, inorganic salts or other excipients.
2. The method of claim 1 , wherein the formulation is administered parenterally.
3. The method of claim 1 , wherein the formulation is administered intramuscularly.
4. The method of claim 1 , wherein the formulation is administered intravenously.
5. The method of claim 1 , wherein the formulation is administered subcutaneously.
6. The method of claim 1 , wherein histidine is at concentration of about 10 to about 30 mM.
7. The method of claim 1 , wherein the formulation has a pH of about 5.0 to about 7.0.
8. The method of claim 1 , wherein the formulation further comprises glycine at a concentration of less than 3.0 mM.
9. The method of claim 1 , the formulation having been prepared by a process in which, for each step of said process, said palivizumab or antigen-binding fragment thereof is in an aqueous phase at all times during preparation.
10. The method of claim 1 , wherein the palivizumab or antigen-binding fragment thereof is not reconstituted lyophilized palivizumab or antigen-binding fragment thereof.
11. The method of claim 1 , wherein the subject is an elderly human, a human with cystic fibrosis, a human with congenital immunodeficiency or acquired immunodeficiency, or a human who has had a bone marrow transplant.
12. The method of claim 1 , wherein the subject is a human infant.
13. The method of claim 1 , wherein the subject is a human infant born prematurely or a human infant at high risk for hospitalization for a RSV infection.
14. The method of claim 1 , wherein the subject is a human with bronchopulmonary dysplasia or congenital heart disease.
15. The method of claim 1 , wherein the formulation is administered to the subject at a dose of about 15 mg/kg to about 30 mg/kg.
16. The method of claim 1 , further comprising the concurrent administration of one or more other therapeutic agents useful for the treatment, management or amelioration of one or more symptoms of a RSV infection.
17. The method of claim 16 , wherein the one or more other therapeutic agent comprises an antibody other than palivizumab that immunospecifically binds to an RSV antigen.
18. The method of claim 1 , wherein the formulation further comprises one or more other therapeutic agents useful for the treatment, management or amelioration of one or more symptoms of a RSV infection.
19. The method of claim 18 , wherein the one or more other therapeutic agent comprises an antibody other than palivizumab that immunospecifically binds to an RSV antigen.
20. A method for preventing serious lower respiratory tract disease caused by RSV in pediatric patients, comprising administering to a pediatric patient an aqueous palivizumab formulation comprising in an aqueous carrier: (a) 103±3 mg/ml of palivizumab or an antigen-binding fragment thereof; (b) histidine at a concentration of about 25 mM; and (c) glycine at a concentration of about 1.6 mM, wherein said formulation has a pH of about 6.0 and does not contain mannitol, and wherein said palivizumab or antigen-binding fragment thereof in the formulation is not reconstituted lyophilized palivizumab or antigen-binding fragment thereof.
21. The method of claim 20 , wherein the formulation is administered parenterally.
22. The method of claim 20 , wherein the formulation is administered intramuscularly.
23. The method of claim 20 , wherein the formulation is administered intravenously.
24. The method of claim 20 , wherein the formulation is administered subcutaneously.
25. The method of claim 20 , the formulation having been prepared by a process in which, for each step of said process, said palivizumab or antigen-binding fragment thereof is in an aqueous phase at all times during preparation.
26. The method of claim 20 , wherein the subject is a human infant.
27. The method of claim 20 , wherein the subject is a human infant born prematurely or a human infant at high risk for hospitalization for a RSV infection.
28. The method of claim 20 , wherein the subject is a human with bronchopulmonary dysplasia or congenital heart disease.
29. The method of claim 20 , wherein the formulation is administered to the subject at a dose of about 15 mg/kg to about 30 mg/kg.
30. The method of claim 20 , further comprising the concurrent administration of one or more other therapeutic agents useful for the treatment, management or amelioration of one or more symptoms of a RSV infection.
31. The method of claim 30 , wherein the one or more other therapeutic agent comprises an antibody other than palivizumab that immunospecifically binds to an RSV antigen.
32. The method of claim 20 , wherein the formulation further comprises one or more other therapeutic agents useful for the treatment, management or amelioration of one or more symptoms of a RSV infection.
33. The method of claim 32 , wherein the one or more other therapeutic agent comprises an antibody other than palivizumab that immunospecifically binds to an RSV antigen.